SG11201907199QA - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
SG11201907199QA
SG11201907199QA SG11201907199QA SG11201907199QA SG11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA SG 11201907199Q A SG11201907199Q A SG 11201907199QA
Authority
SG
Singapore
Prior art keywords
international
janssen
turnhoutseweg
beerse
pct
Prior art date
Application number
SG11201907199QA
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907199Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of SG11201907199QA publication Critical patent/SG11201907199QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
SG11201907199QA 2017-02-06 2018-02-02 Cancer treatment SG11201907199QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
SG11201907199QA true SG11201907199QA (en) 2019-09-27

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201907199QA SG11201907199QA (en) 2017-02-06 2018-02-02 Cancer treatment
SG10202105110VA SG10202105110VA (en) 2017-02-06 2018-02-02 Cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202105110VA SG10202105110VA (en) 2017-02-06 2018-02-02 Cancer treatment

Country Status (26)

Country Link
US (3) US11077106B2 (cg-RX-API-DMAC7.html)
EP (2) EP4286005A3 (cg-RX-API-DMAC7.html)
JP (3) JP2020505425A (cg-RX-API-DMAC7.html)
KR (2) KR20190110581A (cg-RX-API-DMAC7.html)
CN (1) CN110198716A (cg-RX-API-DMAC7.html)
AU (2) AU2018216969B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019016043A2 (cg-RX-API-DMAC7.html)
CA (1) CA3049737A1 (cg-RX-API-DMAC7.html)
DK (1) DK3576740T3 (cg-RX-API-DMAC7.html)
ES (1) ES2953005T3 (cg-RX-API-DMAC7.html)
FI (1) FI3576740T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230697T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062453T2 (cg-RX-API-DMAC7.html)
IL (1) IL268463A (cg-RX-API-DMAC7.html)
JO (1) JOP20190190B1 (cg-RX-API-DMAC7.html)
LT (1) LT3576740T (cg-RX-API-DMAC7.html)
MX (2) MX2019009304A (cg-RX-API-DMAC7.html)
NZ (1) NZ796822A (cg-RX-API-DMAC7.html)
PH (1) PH12019501885A1 (cg-RX-API-DMAC7.html)
PL (1) PL3576740T3 (cg-RX-API-DMAC7.html)
RS (1) RS64778B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201907199QA (cg-RX-API-DMAC7.html)
SI (1) SI3576740T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300233T1 (cg-RX-API-DMAC7.html)
TW (1) TWI874925B (cg-RX-API-DMAC7.html)
UA (1) UA126336C2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
BR112021015686A2 (pt) * 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
MX2021011926A (es) * 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
US20220175768A1 (en) * 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
PH12022552093A1 (en) * 2020-02-12 2023-11-29 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症(covid-19)の予防または治療剤および医薬組成物
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Also Published As

Publication number Publication date
US20260199326A1 (en) 2026-07-16
JOP20190190A1 (ar) 2019-08-04
JP7668777B2 (ja) 2025-04-25
AU2018216969A1 (en) 2019-07-25
EP4286005A2 (en) 2023-12-06
IL268463A (en) 2019-09-26
EP3576740B1 (en) 2023-06-14
CA3049737A1 (en) 2018-08-09
US11077106B2 (en) 2021-08-03
FI3576740T3 (fi) 2023-08-31
MX2019009304A (es) 2019-09-19
AU2018216969B2 (en) 2024-04-11
KR20250069693A (ko) 2025-05-19
ES2953005T3 (es) 2023-11-07
JOP20190190B1 (ar) 2024-04-18
RS64778B1 (sr) 2023-11-30
SI3576740T1 (sl) 2023-10-30
PL3576740T3 (pl) 2023-09-11
CN110198716A (zh) 2019-09-03
PH12019501885A1 (en) 2020-06-29
JP7884578B2 (ja) 2026-07-03
EP4286005A3 (en) 2024-03-06
SMT202300233T1 (it) 2023-09-06
DK3576740T3 (da) 2023-07-24
US20220110935A1 (en) 2022-04-14
HRP20230697T1 (hr) 2023-10-13
JP2023022190A (ja) 2023-02-14
JP2025024064A (ja) 2025-02-19
SG10202105110VA (en) 2021-06-29
MX2022007955A (es) 2022-07-27
KR20190110581A (ko) 2019-09-30
US20200022976A1 (en) 2020-01-23
JP2020505425A (ja) 2020-02-20
HUE062453T2 (hu) 2023-11-28
NZ796822A (en) 2025-12-19
TWI874925B (zh) 2025-03-01
LT3576740T (lt) 2023-08-10
BR112019016043A2 (pt) 2020-03-31
AU2024201871B2 (en) 2026-02-26
AU2024201871A1 (en) 2024-04-11
TW202402290A (zh) 2024-01-16
UA126336C2 (uk) 2022-09-21
NZ755301A (en) 2025-12-19
EP3576740A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201804934PA (en) Novel Compounds
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer